[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558681":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":52,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":19,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":85,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Children's Mercy Hospital Kansas City","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Trihexyphenidyl","EXPERIMENTAL","Participants receive trihexyphenidyl following the dose escalation schedule below:\n\nWeek 1: 0.05 mg\u002Fkg BID Week 2: 0.05 mg\u002Fkg TID Week 3: 0.1 mg\u002Fkg TID Week 4: 0.15 mg\u002Fkg TID Week 5: 0.20 mg\u002Fkg TID Week 6-15: 0.25 mg\u002Fkg TID",[13],"Drug: Trihexyphenidyl",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","6-week dose escalation up to 0.25mg\u002Fkg TID, followed by a 9-week maintenance period at this dose",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Rose Gelineau-Morel, MD","Children's Mercy Kansas City","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","816-302-3331","rngelineaumorel@cmh.edu",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"Rachel Nass","8166011354","rnass@cmh.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Kansas City","Missouri","64108","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-94.57857,39.09973,{"lat":46,"lon":45},[49,51],{"name":31,"role":27,"phone":50,"phoneExt":19,"email":33},"816-601-1354",{"name":22,"role":24,"phone":19,"phoneExt":19,"email":19},{"type":24,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Rose Gelineau-Morel","Principal Investigator",[56],{"name":57,"class":6},"University of Kansas Medical Center","100558681","phase-1-pharmacogenomic-contributions-to-trihexyphenidyl-biotransformation-and-response-in-children-with-dystonic-cerebral-palsy-100558681",false,"NCT06554288","Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy","Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy","TRIKE2","Inclusion Criteria:\n\n* Ages 5-17 years of age\n* Diagnosis of cerebral palsy and dystonia causing interference\n* Parent\u002Flegal guardian of a child with a diagnosis of cerebral palsy and dystonia\n* Parent\u002Flegal guardian is willing and able to provide informed permission\u002Fassent for the study\n\nExclusion Criteria:\n\n* Previously or currently taking trihexyphenidyl\n* Patients turning 18 years of age within the study period (16 weeks from Study Day 1)\n* A language barrier for the patient that precludes communication and\u002For the ability to complete study-related requirements","ALL","5 Years","17 Years",{"count":70,"type":71},40,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.",[77,78,79,80,81,82,83,84],"Pediatric Disorder","Genetic Predisposition","Dystonia, Secondary","Dystonia","Cerebral Palsy, Dystonic-Rigid","Cerebral Palsy, Dyskinetic","Trihexyphenidyl Adverse Reaction","Pharmacogenomic Drug Interaction",[86,87,80,88,9],"Pediatric","Cerebral Palsy","Pharmacogenomics","2026-06-19",{"date":91,"type":92},"2026-06-24","ACTUAL",{"date":94,"type":92},"2024-10-15",{"date":96,"type":71},"2029-12-31",{"name":5,"class":6},1]